Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezo/Bev + FOLFOX-HAIC in High-risk HCC
NCT07272265Completed
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2020
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 6 months. Started Oct 2020; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07272265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272265.